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Cinnamic acids and quinolines are known as useful scaffolds in the discovery of antitumor agents. There-
fore, N-cinnamoylated analogues of chloroquine, recently reported as potent dual-action antimalarials,
were evaluated against three different cancer cell lines: MKN-28, Caco-2, and MCF-7. All compounds dis-
play anti-proliferative activity in the micromolar range against the three cell lines tested, and most of
them were more active than their parent drug, chloroquine, against all cell lines tested. Hence, N-cinnam-
oyl-chloroquine analogues are a good start towards development of affordable antitumor leads.
 2013 Elsevier Ltd. All rights reserved.Cancer remains a life threatening disease worldwide despite of tyrosine kinase, DNA repair, tubulin polymerization, and
available conventional treatments such as surgery, radiotherapy
and/or chemotherapy. The still considerable limitations of cancer
chemotherapy are mainly associated with low efficacy, high toxic-
ity, and emergence of drug resistance, and not less important their
high cost.1 Hence, there is a wide range of scientific approaches to
find better chemotherapeutic agents, including those based on
recycling or repositioning of well-known drugs used to treat dis-
eases other than cancer.2 In this connection, both quinolines and
cinnamic acids, which are found in different natural resources
and widely used for diverse medicinal purposes,3,4 have demon-
strated to constitute scaffolds of great interest for the development
of new antitumor agents.5,6 In one hand, quinoline synthetic versa-
tility promotes the development of large diversity of quinoline
analogues. On the other, the 3-phenyl acrylic acid moiety offers
three main reactive sites: substitutions at the phenyl ring, addi-
tions at the a,b-unsaturated carbonyl moiety, and the carboxylic
acid functionality reactions.5
The specific mechanisms of antitumor action of either quino-
line-based or cinnamic acid-based compounds remain unclear.
However, quinoline derivatives and quinoline alone can inhibitproteasome, and these are just few of the mechanisms of action
which this type of compounds can exert.6 For instance, chloroquine
(CQ), 1 in Figure 1, which is known to inhibit proliferation of breast
cancer cells,7 can cause defects in DNA synthesis and repair, and
also induce cell apoptosis and necrosis.2,8 In the case of cinnamic
acid, it has been reported that one of its modes of action seems
to be inhibition of protein isoprenylation, which blocks mitogenic
signal transduction.4 Still, cinnamic acid analogues have also
shown to be antiangiogenic, antileukemic as well as inhibitors of
transglutaminase, aminopeptidase N, DNA synthesis, and of a spe-
cific tyrosine kinase.5,9 The introduction of a cinnamic acid moiety
has also demonstrated to boost the antitumor activity of parent
antitumor compounds; for instance, distamycin A, 2 in Figure 1,
(IC50 = 7.2 ng/mL) which includes a cinnamoyl functionality,
showed antileukemic activity superior to that presented by talli-
mustine, 3 in Figure 1 (IC50 = 50.3 ng/mL).10,11
In view of the above, the use of cinnamic acid or quinoline scaf-
folds may be beneficial for the development of new antitumor
agents. However, to our knowledge, up today there is no report
in the literature that evaluates the antiproliferative properties of
structures were both the quinoline and cinnamoyl moieties are
linked together. Based on this, and following the drug recycling,
or repurposing, concept,12 we herein report the in vitro antiprolif-
erative properties of chloroquine analogues 4 (Fig. 2), recently re-
ported by us as potent dual-action antimalarials.13,14 Other
Figure 1. Reported examples of quinoline- and cinnamic acid-based compounds with antitumor properties: chloroquine (1), distamicyn A (2) and tallismustine (3).
Figure 2. Chloroquine analogues previously reported as dual-action
antimalarials.14
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were included in the study for a better understanding of struc-
ture–activity relationships (SAR).
Compounds 4–10 were prepared following a straightforward
low-cost synthetic pathway, previously reported, and the analyti-
cal and structural data were in agreement with formerly published
data.13,14 Compounds’ antiproliferative properties against MKN-28
(gastric cancer), Caco-2 (colorectal adenocarcinoma), MCF-7
(breast cancer) and HFF-1 (human foreskin fibroblasts) cell lines
were determined according to the National Cancer Institute (NCI,
USA) procedure, which uses the protein-binding dye sulforhoda-
mine B.15
As shown by data on Table 1, all compounds resulted active in
the micromolar range against the three cancer cell lines used. Fur-
thermore, with the only exceptions of compounds 5, 7 and 8, the
test compounds showed selectivity for MKN-28, Caco-2, and
MCF-7 tumor cells over normal HFF-1 cells. Relevantly, data
obtained clearly shows that the CQ’s heterocyclic core, 4-amino-
7-chloroquinoline, contributes to the enhancement of anti-tumor
activity since (i) its replacement by the 4-aminopyridine one (9
vs 4c) led to a threefold or higher loss in anti-proliferative activity
against the three cancer cell lines tested; (ii) its replacement by the
morpholine core (10 vs 4b) led to an above threefold (MKN-28)
activity loss. Also, all CQ analogues were more active than CQ itself
against the three cancer cell lines tested, except for 5 on Caco-
2 cells.
Additional SAR could be devised by close inspection of in vitro
data of CQ analogues (4a–g, 5–8):
 increasing the length of the alkyl chain leads to an increase of
anti-proliferative activity against Caco-2 and MKN-28 cells, but
has the opposite effect against MFC-7 cells, as shown by com-
parison of compounds 4b vs 6, and 5 vs 4e; also, data from this
former couple of compounds suggest that decreasing chain
length is unfavorable for selectivity; results against the three tumor cell lines used also suggest that
ortho- and para-substituted cinnamoyl groups are preferred over
meta-substituted ones, by comparison of 4f vs 4g and 4d vs 4e;
 removal of the chlorine substituent at the quinoline’s C-7 (7 vs
4b), though leading to an increase of anti-proliferative activity
against all tumor cell lines, had the same effect also against nor-
mal HFF-1 cells, that is, was detrimental for compound
selectivity;
 replacement of the amide bond in 4c by an ester functionality, as
in 8, had a similar effect to that of chlorine removal, since 8 pre-
sented higher anti-proliferative activity than 4c against the four
cell lines tested, that is, activity was increased at the expense of
selectivity loss;
 no obvious correlation could be devised between the stereoelec-
tronic properties of the cinnamoyl substituents (R2) and anti-
proliferative activity.
Finally, we investigated whether the activity displayed by the
CQ analogues could be due to degradation products or metabolites
formed in the course of the experiments. To this end, the stability
of selected test compounds (4b, 6, 7, 9 and 10) in cell culture media
was evaluated through analysis by liquid chromatography hyphen-
ated with electrospray ionization/ion trap mass spectrometry (LC/
ESI-IT MS). All the compounds were confirmed to be stable in those
media, as only one MS peak corresponding to the quasi-molecular
(MH+) ion of each compound was observed in all cases (data not
shown).
The mechanism(s) of action (MOA) through which these CQ
analogues 4 exert their anti-proliferative activity is to be eluci-
dated. Due to the planarity of their aromatic moieties, and resem-
blance to CQ, these compounds might be able to inhibit DNA
replication.16 On the other hand, though with a different global
structure, these CQ analogues share the 4-aminoquinoline and
a,b-unsaturated carbonyl moieties with HKI-272 (11, Fig. 3), a po-
tent inhibitor (IC50 = 59 nM) of the human epidermal growth factor
receptor-2 (HER-2). HER-2 is over-expressed in all three cancer cell
lines used in the present study.17–19 According to the literature,
HKI-272 most likely acts by irreversibly binding to a cysteine in
the ATP-binding pocket of HER-2,20 a behavior that might also be
displayed by our compounds, as their Michael acceptor moiety
could engage in the S-alkylation of the critical Cys residue in
HER-2. Still, this is a highly hypothetical example of what could
be the MOA for our compounds, amongst the wide range of inhibi-
tion processes in which both the quinoline and the Michael accep-
tor moieties could participate, leading to impairment of tumor cell
growth.5,6,21 It could be also argued that, since replacement of the
Table 1
In vitro data of test compounds for antiproliferative activity against MKN-28, Caco-2, and MCF-7
Compound HET n X R2 GI50a GI50 GI50 GI50
(MKN-28) (Caco-2) (MCF-7) (HFF-1)
4a Cq (R1 = Cl) 3 NH H 16.21 ± 0.50 24.14 ± 0.93 14.85 ± 0.90 >100
4b 3 NH p-iPr 22.31 ± 0.37 11.90 ± 0.96 8.09 ± 0.19 >100
4c 3 NH p-OMe 16.90 ± 0.46 30.67 ± 0.63 25.23 ± 0.54 >100
4d 3 NH m-F 15.27 ± 0.73 25.38 ± 0.19 14.85 ± 1.19 >100
4e 3 NH p-F 11.76 ± 0.26 15.03 ± 0.35 12.52 ± 1.94 >100
4f 3 NH o-NO2 15.14 ± 0.16 11.94 ± 0.69 13.30 ± 0.39 >100
4g 3 m-NO2 16.16 ± 0.15 19.32 ± 0.13 59.28 ± 0.56 >100
5 2 NH p-F 34.68 ± 0.85 44.11 ± 0.43 5.24 ± 0.46 44.84 ± 1.95
6 4 NH p-iPr 14.04 ± 0.80 9.16 ± 0.33 20.14 ± 0.68 >100
7 Cq 3 NH p-iPr 5.55 ± 0.20 6.75 ± 0.26 5.24 ± 0.46 39.05 ± 0.60
(R1 = H)
8 Cq 3 O p-OMe 6.60 ± 0.12 17.27 ± 0.64 5.08 ± 0.14 75.21 ± 6.18
(R1 = Cl)
9 Py 3 NH p-OMe 84.52 ± 1.16 >100 77.06 ± 1.79 >100
10 Mu 3 NH p-iPr 72.48 ± 2.89 29.61 ± 3.52 32.69 ± 2.58 >100
CQ 44.44 ± 4.67 38.67 ± 2.64 64.35 ± 2.97 >100
Doxorubicin 0.24 ± 0.03 0.32 ± 0.02 0.31 ± 0.05 >400
a GI50: compound concentration (in lM) causing an inhibition by 50% of cell growth.
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dramatically decrease activity, the antiproliferative activity of
these compounds could be more closely associated to the
N-alkylcinnamoyl building block; that might bring to the scene
MOA related to cinnamic acid derivatives, as inhibition of (i)
phenyltransferases, (ii) protein isoprenylation inhibition, or (iii)
DNA synthesis in growing cells, amongst many other putative
MOA of cinnamoylated compounds. Therefore, any discussion
regarding the possible MOA of these compounds is at this stage
highly speculative and ongoing investigations, in order to iden-
tify a putative target for these compounds, will hopefully shed
some light on this aspect.
In summary, chloroquine analogues 4 have been found to exhi-
bit micromolar activity against three different cancer cell lines:
MKN-28, Caco-2, and MCF-7. Their MOA is yet to be elucidated,
the relevance of the quinoline core for the activity was clearly
demonstrated, since substitution of the quinoline by a pyridine
ring significantly decreased the activity of the compounds.
Moreover, the cinnamoyl moieties seem to contribute toFigure 3. Structure of the HER-2 inhibitor HKI-272 (11).antiproliferative activity of the N-cinnamoylated chloroquinoline
analogues as all compounds 4 displayed activity comparable or
higher than chloroquine alone. Compounds 4 represent a promis-
ing start towards the development of novel affordable leads
against malignant tumor cells, which is a key aspect given that
low and middle-income countries account for about 70% of all can-
cer deaths.22 Further studies are envisaged to inquire the possible
mechanism(s), such as DNA intercalation, underlying antiprolifer-
ative properties displayed by these N-cinnamoylated chloroquine
analogues, and either the reported compounds act prompting
necrosis or apoptosis. Finally, these data reinforce the considerable
therapeutic potential that may be offered by repurposing antimal-
arials such as chloroquine and its derivatives against cancer, a huge
global health burden which is projected to increase in the years to
come.
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